- Partnership with DNDi to Jointly Develop New Treatment for Mycetoma
- Partnership with AAR Japan to Support Its Disease Awareness Program for Mycetoma in Sudan
- Collaborative Project for Mycetoma with AAR Japan Selected for “Projects for global growth of medical technologies, systems and services through human resource development in 2022” by the Ministry of Health, Labour and Welfare, Japan
Eisai aims to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities under its human health care (hhc) concept. One social good that we are focusing on is the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations’ Sustainable Development Goals (SDGs). Mycetoma was officially recognized as the 18th NTD by the World Health Organization (WHO) in 2016. It is said to be one of the most neglected tropical diseases since there is a lack of basic information including its transmission pathway and incidence. To relieve anxieties of patients and the general public suffering from mycetoma, Eisai is engaging in the development of the first-ever mycetoma treatment and disease awareness activities in endemic areas through partnership with Drugs for Neglected Diseases initiative (DNDi), an international non-profit research and development organization, and Association for Aid and Relief, Japan (AAR Japan), an international non-governmental organization.
Animation video emphasizing the collaborations
to tackle mycetoma with partners
Eisai’s Initiatives to Tackle Mycetoma, the Most Neglected Tropical Disease
Eisai’s Initiatives to Tackle Mycetoma, the Most Neglected Tropical Disease
2015
Partnership with DNDi to Jointly Develop New Treatment for Mycetoma
Eisai has signed an agreement with DNDi, a not-for-profit research and development organization, to proceed with the clinical development of Eisai's in-house discovered antifungal agent fosravuconazole (E1224) as a new treatment for mycetoma. Currently, a Phase Ⅱ/Ⅲ study is underway in the Mycetoma Research Centre (MRC) in Sudan, one of the countries where the disease is most prevalent. This project is supported by the Global Health Innovative Technology Fund (GHIT Fund), Japan's first public–private partnership to advance development of new health technologies for the developing world. Please click here for more details.
2019
Partnership with AAR Japan to Support Its Disease Awareness Program for Mycetoma in Sudan
As an international non-governmental organization founded in Japan, AAR Japan is conducting disease awareness activities and providing medical support to promote patients’ early diagnosis and treatment at medical institutions in Sudan, the country where mycetoma is most prevalent. Eisai has been supporting AAR Japan’s program to tackle mycetoma since 2019, contributing to the local communities by providing treatment and surgery to approximately 100 mycetoma patients and conducting disease awareness activities for more than 2,400 residents since the start of our collaboration. We are expanding collaborations with AAR Japan based on shared mid-term activity goals to fight against mycetoma via a holistic and sustainable solution, which includes psychological care to post-operative patients and capacity building for local organization. Please click here for more details.
2022
Collaborative Project for Mycetoma with AAR Japan Selected for “Projects for global growth of medical technologies, systems and services through human resource development in 2022” by the Ministry of Health, Labour and Welfare, Japan
The project “Capacity Building and Awareness Raising Project for Mycetoma Infection Control in Sudan” in collaboration with AAR Japan has been selected for “Projects for global growth of medical technologies, systems and services through human resource development in 2022” by the Ministry of Health, Labour and Welfare, Japan. As part of this project, we are conducting online training for cooperative organizations and healthcare professionals involved in local mycetoma countermeasures in Sudan with the cooperation of the Institute of Tropical Medicine, Nagasaki University. At the online training, we introduce our activities with AAR Japan for mycetoma, development of mycetoma treatment utilizing Eisai's in-house discovered antifungal agent fosravuconazole (E1224) via partnership, as well as the importance of One Health initiative, a cross-cutting approach to improve health of humans and animals, and environment.
a network to combat NTDs in Sudan
Source: AAR Japan Activity Report (Japanese)
Please click here to see our latest articles about local activities.
